The psychedelic medicine landscape is rapidly evolving, with new research demonstrating therapeutic potential and jurisdictions beginning to reform laws. As momentum builds around psilocybin, MDMA, and other psychedelic compounds, what steps can policymakers take to support safe patient access and scientific progress? In this timely discussion, expert panelists closely monitoring federal policy developments will provide key insights for the psychedelics policy reform movement. They’ll examine the prospects for federal re- or de-scheduling efforts, discuss Congressional appetite for pro-psychedelic legislation, and explore FDA’s evolving regulatory approach as novel psychedelic therapies approach approval.